Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis

Company Overview

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Key Stats

• Today's Range: $43.09 to $44.54
• 50-Day Range: $43.62 to $53.40
• 52-Week Range: $36.56 to $65.92
• Volume: 607,136 shs
• Average Volume: 398,103 shs
• Market Capitalization: $2.12 billion
• P/E Ratio: 14.70
• Dividend Yield: N/A
• Price Target: $63.00
• Consensus Rating: Moderate Buy

Amphastar Pharmaceuticals Stock Analysis - MarketRank™

Amphastar Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 70th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Amphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Amphastar Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 14.57%

Earnings Growth

Earnings for Amphastar Pharmaceuticals are expected to grow by 14.57% in the coming year, from $3.57 to $4.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amphastar Pharmaceuticals is 14.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.48.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amphastar Pharmaceuticals is 14.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 135.41.

Price to Earnings Growth Ratio

Amphastar Pharmaceuticals has a PEG Ratio of 0.89. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Amphastar Pharmaceuticals has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.16% of the float of Amphastar Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Amphastar Pharmaceuticals has recently increased by 2.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amphastar Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Amphastar Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -2.21

Percentage of Shares Shorted

12.16% of the float of Amphastar Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Amphastar Pharmaceuticals has recently increased by 2.60%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.18

News Sentiment

Amphastar Pharmaceuticals has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for AMPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,571,652.00 in company stock.

Percentage Held by Insiders

27.10% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AMPH Stock Analysis - Frequently Asked Questions

How have AMPH shares performed this year?

Amphastar Pharmaceuticals' stock was trading at $61.85 at the start of the year. Since then, AMPH stock has decreased by 28.7% and is now trading at $44.09.
View the best growth stocks for 2024 here.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings results on Monday, November, 8th. The company reported $0.46 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $0.22. The company had revenue of $112.20 million for the quarter, compared to analysts' expectations of $103 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 26.44% and a net margin of 21.80%.

Who are Amphastar Pharmaceuticals' major shareholders?

Top institutional investors of Amphastar Pharmaceuticals include State Street Corp (3.18%), Geode Capital Management LLC (1.91%), Boston Trust Walden Corp (1.10%) and Charles Schwab Investment Management Inc. (0.72%). Insiders that own company stock include Jack Y Zhang, Mary Z Luo, Howard Lee, Rong Zhou, William J Peters, Floyd F Petersen, Yakob Liawatidewi, Richard K Prins, Michael A Zasloff and Diane G Gerst.
View institutional ownership trends.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AMPH
• CUSIP: N/A
• CIK: 1297184
• Web: www.amphastar.com
• Phone: (909) 980-9484
• Fax: 909-980-8296
• Employees: 1,761
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $63.00
• High Stock Price Target: $66.00
• Low Stock Price Target: $60.00
• Potential Upside/Downside: +42.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $3.00
• Trailing P/E Ratio: 14.70
• Forward P/E Ratio: 12.35
• P/E Growth: 0.89
• Net Income: $137.54 million
• Net Margins: 21.80%
• Pretax Margin: 25.86%
• Return on Equity: 26.44%
• Return on Assets: 11.89%

Debt

• Debt-to-Equity Ratio: 0.82
• Current Ratio: 3.43
• Quick Ratio: 2.61

Sales & Book Value

• Annual Sales: $644.40 million
• Price / Sales: 3.29
• Cash Flow: $4.31 per share
• Price / Cash Flow: 10.22
• Book Value: $13.35 per share
• Price / Book: 3.30

Miscellaneous

• Outstanding Shares: 48,080,000
• Free Float: 35,051,000
• Market Cap: $2.12 billion
• Optionable: Optionable
• Beta: 0.82